Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $295.87 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 0.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 500,929 shares of the medical research company’s stock after buying an additional 4,619 shares during the quarter. Thermo Fisher Scientific accounts for approximately 3.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 11th largest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.13% of Thermo Fisher Scientific worth $295,874,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Marietta Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 4.3% during the 1st quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock worth $7,626,000 after purchasing an additional 529 shares in the last quarter. California State Teachers Retirement System increased its holdings in Thermo Fisher Scientific by 0.6% during the 4th quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock worth $472,459,000 after purchasing an additional 4,340 shares in the last quarter. Aries Wealth Management increased its holdings in Thermo Fisher Scientific by 611.7% during the 4th quarter. Aries Wealth Management now owns 33,285 shares of the medical research company’s stock worth $22,209,000 after purchasing an additional 28,608 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Thermo Fisher Scientific during the 4th quarter worth about $197,400,000. Finally, Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 24,890 shares of the medical research company’s stock valued at $16,608,000 after acquiring an additional 262 shares in the last quarter. 87.48% of the stock is currently owned by institutional investors and hedge funds.

In other news, COO Michel Lagarde sold 13,030 shares of the company’s stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the transaction, the chief operating officer now owns 15,758 shares in the company, valued at $8,903,900.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $545.60, for a total transaction of $5,456,000.00. Following the completion of the sale, the chief executive officer now owns 183,373 shares in the company, valued at approximately $100,048,308.80. The disclosure for this sale can be found here. Insiders sold 42,561 shares of company stock worth $23,557,413 over the last three months. 0.43% of the stock is currently owned by insiders.

Shares of NYSE TMO traded up $10.76 during midday trading on Thursday, reaching $529.98. The company’s stock had a trading volume of 17,628 shares, compared to its average volume of 1,216,127. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.10 and a current ratio of 1.56. Thermo Fisher Scientific Inc. has a fifty-two week low of $489.14 and a fifty-two week high of $672.34. The business’s 50 day moving average price is $544.31 and its two-hundred day moving average price is $575.26. The company has a market cap of $207.47 billion, a P/E ratio of 27.07, a P/E/G ratio of 1.74 and a beta of 0.83.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last released its quarterly earnings results on Thursday, April 28th. The medical research company reported $7.25 earnings per share for the quarter, beating analysts’ consensus estimates of $6.17 by $1.08. The company had revenue of $11.82 billion during the quarter, compared to the consensus estimate of $10.66 billion. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The firm’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned $7.21 earnings per share. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.7 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be paid a $0.30 dividend. The ex-dividend date is Tuesday, June 14th. This represents a $1.20 dividend on an annualized basis and a yield of 0.23%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.26%.

Several equities analysts have recently weighed in on the company. Wells Fargo & Company cut Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $605.00 to $525.00 in a report on Monday, April 25th. StockNews.com assumed coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $658.92.

About Thermo Fisher Scientific (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.